Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers.

The decision to clear another mifepristone generic sparked political backlash. Elsewhere, Medicare delayed a decision on whether to subject “combination” drugs to pricing negotiations, and a cancer ...

In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see as a superior version of the now-withdrawn gout medication Zurampic.

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily pain. Doctors fear that’s bound to continue.

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new Novartis drug and two biotechs cut staff.

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable type of hormone therapy.

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential competitor to Soleno’s fast-selling Vykat.

The company is working on T cell engagers and other multifunctional antibodies, led by a prospect it believes might be ...

The company has received a “limited number” of non-binding proposals, mostly from groups of financial investors, for a business that was once its primary focus.

The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with significant layoffs and leadership upheaval this year.